Skip to main content

Risperidone-associated diabetes mellitus: a pharmacovigilance study.

Publication ,  Journal Article
Koller, EA; Cross, JT; Doraiswamy, PM; Schneider, BS
Published in: Pharmacotherapy
June 2003

STUDY OBJECTIVE: To explore the clinical characteristics of hyperglycemia in patients treated with risperidone. DESIGN: Pharmacovigilance survey of spontaneously reported adverse events in risperidone-treated patients, with reports of haloperidol-associated hyperglycemia used as a control. SETTING: Government-affiliated drug evaluation center. INTERVENTION: The Food and Drug Administration MedWatch surveillance program was queried (risperidone, 1993-February 2002; haloperidol, late 1970s-February 2002) and results pooled with published cases. MEASUREMENTS AND MAIN RESULTS: We identified 131 reports of risperidone-associated hyperglycemia in addition to seven reports of patients with hyperglycemia who received combined risperidone-haloperidol therapy and six reports of acidosis that occurred in the absence of hyperglycemia. We found 13 reports of haloperidol-associated hyperglycemia and 11 reports of acidosis without hyperglycemia. Of the reports of risperidone-associated hyperglycemia (monotherapy), 78 patients had newly diagnosed hyperglycemia, 46 had exacerbated preexisting diabetes, and 7 could not be classified. Mean +/- SD age was 39.8 +/- 17.4 years (range 8-96 yrs). Patients with new-onset diabetes (mean +/- SD age 34.8 +/- 15.7 yrs) were younger than those with preexisting diabetes (mean +/- SD age 48.8 +/- 17.5 yrs). The overall male:female ratio was 1.5. In most patients, hyperglycemia appeared within 3 months of the start of risperidone therapy. Severity of disease ranged from mild glucose intolerance to diabetic ketoacidosis or hyperosmolar coma. Twenty-six patients with acidosis or ketosis were reported. Four patients died. CONCLUSION: Atypical antipsychotic treatment may unmask or precipitate hyperglycemia. Although such cases attributed to clozapine or olanzapine are more numerous than those associated with risperidone, the number for risperidone-associated hyperglycemia is relatively higher than that observed with the conventional neuroleptic haloperidol.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Pharmacotherapy

DOI

ISSN

0277-0008

Publication Date

June 2003

Volume

23

Issue

6

Start / End Page

735 / 744

Location

United States

Related Subject Headings

  • United States
  • Risperidone
  • Risk Factors
  • Product Surveillance, Postmarketing
  • Pharmacology & Pharmacy
  • Middle Aged
  • Male
  • MEDLINE
  • Hyperglycemia
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Koller, E. A., Cross, J. T., Doraiswamy, P. M., & Schneider, B. S. (2003). Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy, 23(6), 735–744. https://doi.org/10.1592/phco.23.6.735.32178
Koller, Elizabeth A., James T. Cross, P Murali Doraiswamy, and Bruce S. Schneider. “Risperidone-associated diabetes mellitus: a pharmacovigilance study.Pharmacotherapy 23, no. 6 (June 2003): 735–44. https://doi.org/10.1592/phco.23.6.735.32178.
Koller EA, Cross JT, Doraiswamy PM, Schneider BS. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy. 2003 Jun;23(6):735–44.
Koller, Elizabeth A., et al. “Risperidone-associated diabetes mellitus: a pharmacovigilance study.Pharmacotherapy, vol. 23, no. 6, June 2003, pp. 735–44. Pubmed, doi:10.1592/phco.23.6.735.32178.
Koller EA, Cross JT, Doraiswamy PM, Schneider BS. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy. 2003 Jun;23(6):735–744.

Published In

Pharmacotherapy

DOI

ISSN

0277-0008

Publication Date

June 2003

Volume

23

Issue

6

Start / End Page

735 / 744

Location

United States

Related Subject Headings

  • United States
  • Risperidone
  • Risk Factors
  • Product Surveillance, Postmarketing
  • Pharmacology & Pharmacy
  • Middle Aged
  • Male
  • MEDLINE
  • Hyperglycemia
  • Humans